275 related articles for article (PubMed ID: 27671675)
1. FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia.
Traer E; Martinez J; Javidi-Sharifi N; Agarwal A; Dunlap J; English I; Kovacsovics T; Tyner JW; Wong M; Druker BJ
Cancer Res; 2016 Nov; 76(22):6471-6482. PubMed ID: 27671675
[TBL] [Abstract][Full Text] [Related]
2. Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.
Zhang W; Gao C; Konopleva M; Chen Y; Jacamo RO; Borthakur G; Cortes JE; Ravandi F; Ramachandran A; Andreeff M
Clin Cancer Res; 2014 May; 20(9):2363-74. PubMed ID: 24619500
[TBL] [Abstract][Full Text] [Related]
3. A Genome-Wide CRISPR Screen Identifies Genes Critical for Resistance to FLT3 Inhibitor AC220.
Hou P; Wu C; Wang Y; Qi R; Bhavanasi D; Zuo Z; Dos Santos C; Chen S; Chen Y; Zheng H; Wang H; Perl A; Guo D; Huang J
Cancer Res; 2017 Aug; 77(16):4402-4413. PubMed ID: 28625976
[TBL] [Abstract][Full Text] [Related]
4. Internal tandem duplication of FLT3 deregulates proliferation and differentiation and confers resistance to the FLT3 inhibitor AC220 by Up-regulating RUNX1 expression in hematopoietic cells.
Hirade T; Abe M; Onishi C; Taketani T; Yamaguchi S; Fukuda S
Int J Hematol; 2016 Jan; 103(1):95-106. PubMed ID: 26590920
[TBL] [Abstract][Full Text] [Related]
5. Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinase.
Yang X; Sexauer A; Levis M
Br J Haematol; 2014 Jan; 164(1):61-72. PubMed ID: 24116827
[TBL] [Abstract][Full Text] [Related]
6. Over-expression of FoxM1 is associated with adverse prognosis and FLT3-ITD in acute myeloid leukemia.
Liu LL; Zhang DH; Mao X; Zhang XH; Zhang B
Biochem Biophys Res Commun; 2014 Mar; 446(1):280-5. PubMed ID: 24582753
[TBL] [Abstract][Full Text] [Related]
7. Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns.
Moore AS; Faisal A; Gonzalez de Castro D; Bavetsias V; Sun C; Atrash B; Valenti M; de Haven Brandon A; Avery S; Mair D; Mirabella F; Swansbury J; Pearson AD; Workman P; Blagg J; Raynaud FI; Eccles SA; Linardopoulos S
Leukemia; 2012 Jul; 26(7):1462-70. PubMed ID: 22354205
[TBL] [Abstract][Full Text] [Related]
8. Quizartinib (AC220): a promising option for acute myeloid leukemia.
Zhou F; Ge Z; Chen B
Drug Des Devel Ther; 2019; 13():1117-1125. PubMed ID: 31114157
[TBL] [Abstract][Full Text] [Related]
9. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.
Smith CC; Wang Q; Chin CS; Salerno S; Damon LE; Levis MJ; Perl AE; Travers KJ; Wang S; Hunt JP; Zarrinkar PP; Schadt EE; Kasarskis A; Kuriyan J; Shah NP
Nature; 2012 Apr; 485(7397):260-3. PubMed ID: 22504184
[TBL] [Abstract][Full Text] [Related]
10. Microenvironmental CXCL12 deletion enhances Flt3-ITD acute myeloid leukemia stem cell response to therapy by reducing p38 MAPK signaling.
Anderson NR; Sheth V; Li H; Harris MW; Qiu S; Crossman DK; Kumar H; Agarwal P; Nagasawa T; Paterson AJ; Welner RS; Bhatia R
Leukemia; 2023 Mar; 37(3):560-570. PubMed ID: 36550214
[TBL] [Abstract][Full Text] [Related]
11. A dual inhibitor overcomes drug-resistant FLT3-ITD acute myeloid leukemia.
Wang P; Xiao X; Zhang Y; Zhang B; Li D; Liu M; Xie X; Liu C; Liu P; Ren R
J Hematol Oncol; 2021 Jul; 14(1):105. PubMed ID: 34217323
[TBL] [Abstract][Full Text] [Related]
12. Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation.
Kapoor S; Natarajan K; Baldwin PR; Doshi KA; Lapidus RG; Mathias TJ; Scarpa M; Trotta R; Davila E; Kraus M; Huszar D; Tron AE; Perrotti D; Baer MR
Clin Cancer Res; 2018 Jan; 24(1):234-247. PubMed ID: 29074603
[No Abstract] [Full Text] [Related]
13. Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.
Smith CC; Lasater EA; Zhu X; Lin KC; Stewart WK; Damon LE; Salerno S; Shah NP
Blood; 2013 Apr; 121(16):3165-71. PubMed ID: 23430109
[TBL] [Abstract][Full Text] [Related]
14. Novel AXL-targeted agents overcome FLT3 inhibitor resistance in FLT3-ITD
Liu Y; Wei J; Liu J; Ma W; Duan Y; Liu D
Oncol Lett; 2021 May; 21(5):397. PubMed ID: 33777220
[TBL] [Abstract][Full Text] [Related]
15. FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia.
Long J; Jia MY; Fang WY; Chen XJ; Mu LL; Wang ZY; Shen Y; Xiang RF; Wang LN; Wang L; Jiang CH; Jiang JL; Zhang WJ; Sun YD; Chang L; Gao WH; Wang Y; Li JM; Hong DL; Liang AB; Hu J
Blood; 2020 Apr; 135(17):1472-1483. PubMed ID: 32315388
[TBL] [Abstract][Full Text] [Related]
16. Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models.
Singh Mali R; Zhang Q; DeFilippis RA; Cavazos A; Kuruvilla VM; Raman J; Mody V; Choo EF; Dail M; Shah NP; Konopleva M; Sampath D; Lasater EA
Haematologica; 2021 Apr; 106(4):1034-1046. PubMed ID: 32414851
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.
Maifrede S; Nieborowska-Skorska M; Sullivan-Reed K; Dasgupta Y; Podszywalow-Bartnicka P; Le BV; Solecka M; Lian Z; Belyaeva EA; Nersesyan A; Machnicki MM; Toma M; Chatain N; Rydzanicz M; Zhao H; Jelinek J; Piwocka K; Sliwinski T; Stoklosa T; Ploski R; Fischer T; Sykes SM; Koschmieder S; Bullinger L; Valent P; Wasik MA; Huang J; Skorski T
Blood; 2018 Jul; 132(1):67-77. PubMed ID: 29784639
[TBL] [Abstract][Full Text] [Related]
18. Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells.
Larrue C; Saland E; Boutzen H; Vergez F; David M; Joffre C; Hospital MA; Tamburini J; Delabesse E; Manenti S; Sarry JE; RĂ©cher C
Blood; 2016 Feb; 127(7):882-92. PubMed ID: 26286850
[TBL] [Abstract][Full Text] [Related]
19. Role of CYP3A4 in bone marrow microenvironment-mediated protection of FLT3/ITD AML from tyrosine kinase inhibitors.
Chang YT; Hernandez D; Alonso S; Gao M; Su M; Ghiaur G; Levis MJ; Jones RJ
Blood Adv; 2019 Mar; 3(6):908-916. PubMed ID: 30898762
[TBL] [Abstract][Full Text] [Related]
20. Internal Tandem Duplication in FLT3 Attenuates Proliferation and Regulates Resistance to the FLT3 Inhibitor AC220 by Modulating p21Cdkn1a and Pbx1 in Hematopoietic Cells.
Abe M; Pelus LM; Singh P; Hirade T; Onishi C; Purevsuren J; Taketani T; Yamaguchi S; Fukuda S
PLoS One; 2016; 11(7):e0158290. PubMed ID: 27387666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]